1. Introduction {#sec1-biosensors-08-00132}
===============

Biosensors are the subject of enormous expectations and are gradually gaining in diagnostic importance. These expectations are connected with what is called "liquid biopsy" (i.e., diagnosis based on analysis of body fluids such as blood, urine, and saliva, and the possibility of early diagnosis of various cancers). However, there is still a shortage of biosensors offering near 100% sensitivity and specificity (i.e., 100% of true positive and 100% of correctly rejected results, respectively). An ideal biosensor should react exclusively to the target marker despite the presence of numerous similar proteins, glycoproteins, and others in the analyzed body fluid. Moreover, the biosensor's dynamic response range should include the concentrations of the marker found in the body fluid, both of persons with the disease and of the healthy population. It is also expected that the precision of measurement of the marker concentration will be sufficient to distinguish between samples below and above a "cut-off" value.

A limited number of measuring techniques are used successfully in combination with biosensors, the leader among which is ELISA. Surface Plasmon Resonance (SPR) is still only a promising technique, which so far has no practical diagnostic applications. However, the number of potential applications of SPR in the solution of real clinical problems is growing.

This paper reviews the most recent publications on SPR biosensors, appearing between 2016 and mid-2018. Earlier works are covered in an excellent review by Masson (2017) \[[@B1-biosensors-08-00132]\]. This review excludes papers concerning SPR biosensors used for the determination of large particles such as vesicles, exosomes, cancer cells, living cells, and stem cells, as well as microRNA---these papers have already been broadly reviewed \[[@B2-biosensors-08-00132]\]. Both Masson and Ferhan et al. conclude that future work should focus more on clinical samples than on improving detection specificity and sensitivity.

2. Stages of Biosensor Development {#sec2-biosensors-08-00132}
==================================

Generally, a mature biosensor and a procedure for the determination of a particular marker are developed in several stages, beginning with the conception of the biosensor, followed by analytical characterization, validation, and determination of the marker in real samples. Therefore, the reviewed papers are categorized into five groups, depending on the degree of maturity of the reported solution. The following stages of development of a biosensor and a related analytical procedure can be distinguished:The biosensor is used only for the detection of a marker;The biosensor is characterized in terms of quantitative marker determination (calibration graph, the marker concentration range covered by the biosensor);The biosensor and related analytical procedure are validated (precision, recovery, interferences, comparison of results with another procedure such as ELISA, examples of natural samples, e.g., blood plasma);The mature biosensor and the analytical procedure are used for investigation of the marker in significant series of clinical samples, including long control series of healthy donors;A fifth stage may be distinguished when the mature SPR biosensor and procedure are used in clinical investigation.

This categorization proves to be useful in relation to the papers considered in this review. The papers pertaining to stages (i) and (ii) represent incomplete analytical procedures. Technical solutions applied in these biosensors are shown in [Table 1](#biosensors-08-00132-t001){ref-type="table"} \[[@B3-biosensors-08-00132],[@B4-biosensors-08-00132],[@B5-biosensors-08-00132],[@B6-biosensors-08-00132],[@B7-biosensors-08-00132],[@B8-biosensors-08-00132],[@B9-biosensors-08-00132],[@B10-biosensors-08-00132],[@B11-biosensors-08-00132],[@B12-biosensors-08-00132],[@B13-biosensors-08-00132]\]. These papers represent high innovative potential in terms of biosensor construction, which may result in fully developed procedures in the future.

An example of a paper pertaining to stage (i) is a report on the detection of CEA in the blood of colon cancer patients \[[@B4-biosensors-08-00132]\]. CEA is captured from the blood serum by the mouse anti-CEA antibody immobilized on the biosensor surface. A significantly higher SPR signal is produced by colon cancer samples than by samples from healthy donors. However, that study did not include calibration or CEA quantification---in contrast to a paper by Chiu et al. \[[@B10-biosensors-08-00132]\], where quantification of CYFRA 21-1 in spiked human blood was performed on the basis of a calibration curve. CYFRA 21-1 is a circulating fragment of creatinine-19 which is a marker for cancer, including lung cancer. Due to the lack of validation of the developed biosensor, this paper pertains to stage (ii).

The papers pertaining to stages (iii) and (iv) represent complete analytical procedures \[[@B14-biosensors-08-00132],[@B15-biosensors-08-00132],[@B16-biosensors-08-00132],[@B17-biosensors-08-00132],[@B18-biosensors-08-00132],[@B19-biosensors-08-00132],[@B20-biosensors-08-00132],[@B21-biosensors-08-00132],[@B22-biosensors-08-00132],[@B23-biosensors-08-00132],[@B24-biosensors-08-00132],[@B25-biosensors-08-00132],[@B26-biosensors-08-00132],[@B27-biosensors-08-00132]\]. These biosensors and related analytical procedures are ready to be subjected to clinical investigation for subsequent use in diagnosis. Additionally, biosensors in stage (iv) are characterized as potential disease markers by a series of measurements performed with clinically classified material. An example of a paper pertaining to stage (iii) is a report on the determination of PSA in human serum \[[@B14-biosensors-08-00132]\]. PSA concentration was quantified on the basis of a calibration curve. The developed biosensor and related analytical procedures were validated by parallel PSA determination using ELISA in series of blood serum samples spiked with PSA. Apart from analytical characteristics such as a calibration curve, precision determination and potential interferences, papers pertaining to stage (iv) contain the results of marker determination in series of clinically classified samples. An example is a paper on a biosensor and procedure for the determination of laminin-5 in human blood plasma \[[@B20-biosensors-08-00132]\]. This paper describes the optimization of parameters, as well as characteristics relating to precision, recovery and potential interferences. To validate the biosensor, laminin-5 was determined by ELISA and by the developed biosensor in two series of samples; the first containing samples from bladder cancer patients, and the second containing samples of healthy donors.

Technical solutions for biosensors representing completely developed procedures are shown in [Table 2](#biosensors-08-00132-t002){ref-type="table"}.

The number of biosensors placed in this category outnumber those with incomplete analytical procedures shown in [Table 1](#biosensors-08-00132-t001){ref-type="table"}. This is a positive observation and a good prognostic factor for future SPR biosensors.

Papers pertaining to stage (v) \[[@B28-biosensors-08-00132],[@B29-biosensors-08-00132],[@B30-biosensors-08-00132],[@B31-biosensors-08-00132],[@B32-biosensors-08-00132],[@B33-biosensors-08-00132],[@B34-biosensors-08-00132],[@B35-biosensors-08-00132],[@B36-biosensors-08-00132],[@B37-biosensors-08-00132]\] represent completely developed analytical procedures that have been applied in various clinical investigations. An example is a paper reporting the determination of three markers, laminin-5, collagen IV, and matrix metalloproteinase-2, in the blood plasma of pediatric burn patients \[[@B32-biosensors-08-00132]\]. The methods for the determination of these markers had been developed and published previously, and the paper cited here merely reports an application of those solutions.

Technical solutions for developed biosensors applied in clinical investigations are shown in [Table 3](#biosensors-08-00132-t003){ref-type="table"}.

The numerous applications of previously developed biosensors provide evidence of their effectiveness. As [Table 1](#biosensors-08-00132-t001){ref-type="table"}, [Table 2](#biosensors-08-00132-t002){ref-type="table"} and [Table 3](#biosensors-08-00132-t003){ref-type="table"} show, a majority of the reviewed papers present mature solutions or are devoted to the application of previously developed biosensors in clinical investigations. This is a tendency corresponding to that recommended in the reviews by Mansson and Ferhan et al. \[[@B1-biosensors-08-00132],[@B2-biosensors-08-00132]\], and gives an indication of the future growing significance of SPR.

3. Fluidic vs. Non-Fluidic Measurements {#sec3-biosensors-08-00132}
=======================================

Approximately the same number of reviewed papers reported the use of fluidic and non-fluidic measurement. In two cases, the use of both options as alternatives was reported, and in five cases fluidic measurements were performed as microfluidic. There is a significant difference in the arrangement of a fluidic or non-fluidic measurement; a fluidic measurement is usually performed with in situ creation of a biosensor, while in the non-fluidic case the biosensor is prepared ex situ. In the fluidic version a biosensor is created during the measurement by sequential introduction of a linker, a receptor and a solution containing the determined marker. Measurement is performed with the biosensor in contact with solution. This is the major difference from the non-fluidic case. An example of fluidic SPR measurement is shown in [Figure 1](#biosensors-08-00132-f001){ref-type="fig"}. Finally, the chip sensor is cleaned to prepare it for the next measurement. Subsequent measurements can be performed rapidly, as in flow-injection analysis.

A single biosensor usually contains several channels, processed simultaneously for multi-sample measurement or for processing the same solution to gain better precision. The volume of processed solution is the main difference between fluidic and microfluidic techniques; in the microfluidic case there is a tendency towards the miniaturization of the measuring process. Microfluidic measurement also uses an array of measuring points (see [Figure 2](#biosensors-08-00132-f002){ref-type="fig"} and \[[@B3-biosensors-08-00132]\]).

Non-fluidic measurement is usually performed in a stationary arrangement, with an array of separated measuring points. An example of non-fluidic measurement is shown in [Figure 3](#biosensors-08-00132-f003){ref-type="fig"}. An array of measuring points is used for a single measurement to improve the precision of the result. Multi-sample measurement is also performed, as shown in [Figure 3](#biosensors-08-00132-f003){ref-type="fig"}, as well as regeneration of the chip after measurement.

Non-fluidic SPR measurement is performed following gentle drying of the biosensor, which is the major difference as compared with fluidic measurements.

No information has yet been published concerning the comparison of fluidic and non-fluidic versions of SPR measurements. As regards instrumental solutions, both classical SPR and SPR imaging are equally represented; the imaging version is frequently associated with non-fluidic measurement.

4. Receptors {#sec4-biosensors-08-00132}
============

A crucial part of a biosensor is the receptor. The receptor must ensure that only the target marker is captured from the analyzed sample, as well as ensuring suitable effectiveness in terms of the strength of analytical signal sufficient for the determination of a marker in real samples. In the reviewed papers, appropriate antibodies were most frequently used as receptors. The antibody was attached to the gold chip surface via a linker. Most frequently, cysteamine (2-aminoethanethiol) was used as the linker. Cysteamine is fixed onto the gold surface by the thiol group, while the amine group is used for attachment of the antibody. An example of such receptor immobilization is shown in [Figure 4](#biosensors-08-00132-f004){ref-type="fig"}.

An EDC/NHS protocol is applied for this purpose, with amide bond formation between the antibody's carboxyl group and the linker's amine group. Alternatively, MUA (11-mercaptoundecanoic acid) may be used in conjunction with the EDC/NHS protocol \[[@B4-biosensors-08-00132]\]. The amine group of the antibody is used for the junction. Similarly, HS-OEG-COOH \[[@B38-biosensors-08-00132]\], S2PEG6COOH \[[@B5-biosensors-08-00132]\] (where OEG and PEG denote oxyethylene subunits), and mercapto-propane sulfonate \[[@B8-biosensors-08-00132]\] have been used. In numerous papers, the commercially available CM5 chip with carboxylated dextran as the linker was employed. Another commercially available chip (Easy2Spot) is supplied in a form ready for antibody bonding \[[@B6-biosensors-08-00132]\].

Several solutions other than antibodies have been used as receptors. A marker's inhibitor can be used as the receptor, as in the cases of the inhibitor ONX 0914 \[[@B23-biosensors-08-00132]\] and the inhibitor ARP 101 \[[@B24-biosensors-08-00132]\]; in both cases 1-octadecano-thiol was used as the linker, and the inhibitor was attached to the linker via hydrophobic interactions. An example of this type of receptor immobilization is shown in [Figure 5](#biosensors-08-00132-f005){ref-type="fig"}. A receptor-imprinted polymer may also be used as the receptor \[[@B14-biosensors-08-00132],[@B16-biosensors-08-00132]\].

A glass slide covered with gold is a typical chip base (see the example in [Figure 4](#biosensors-08-00132-f004){ref-type="fig"}). Alternatively, a gold-covered glass prism is used. Usually, a chromium, or alternatively titanium, under-layer is employed. Only a few papers report other solutions, such as a gold-covered glass fiber \[[@B5-biosensors-08-00132]\], also with additional graphene layer \[[@B39-biosensors-08-00132]\], a gold nanohole array \[[@B3-biosensors-08-00132],[@B40-biosensors-08-00132]\], or a prism covered with gold and graphene \[[@B41-biosensors-08-00132]\]. Frequently, a gold chip surface is covered by a polymer with holes, creating an array of free gold measuring points. A thick inert polycarbonate protective layer is also proposed \[[@B42-biosensors-08-00132]\].

5. Enhancement of the SPR Signal {#sec5-biosensors-08-00132}
================================

As demonstrated by Brolo's research group in Canada, periodic areas of nanoholes in a sandwich configuration may be used to enhance the SPR signal \[[@B3-biosensors-08-00132]\]. The first antibody captures the marker, while the marker captures the second antibody. The introduction of different nanoparticles in the sandwich can lead to much greater enhancement of the SPR signal. [Table 4](#biosensors-08-00132-t004){ref-type="table"} summarizes the cases in which nanoparticles were applied. In the simplest solution, the first antibody attached by the EDC/NHS protocol captures the marker, which captures an aggregate consisting of a gold nanoparticle covered by a second antibody attached to the antibody surface by the same EDC/NHS protocol \[[@B38-biosensors-08-00132]\]. An example is shown in [Figure 6](#biosensors-08-00132-f006){ref-type="fig"}. A similar solution is reported \[[@B43-biosensors-08-00132]\] in which the EDC/NHS protocol is used for the first antibody attachment, and a biotinylated antibody attached to streptavidin-decorated gold nanoparticles serves as the second. The preconcentration of the marker with magnetic microparticles covered by the antibody has been reported \[[@B44-biosensors-08-00132]\]. Finally, the signal is created indirectly by a selected aptamer released from the magnetic microparticles-antibody-marker-aptamer structure. A quantum dot having a CdSe and ZnS core or shell structure has also been used for SPR signal enhancement in a sandwich configuration \[[@B45-biosensors-08-00132]\], as have polydopamine-wrapped magnetic multi-walled carbon nanotubes \[[@B46-biosensors-08-00132]\].

6. Calibration Strategy {#sec6-biosensors-08-00132}
=======================

In our opinion, the most significant information concerning the calibration strategy is whether the range of measurable concentration covers the range of concentrations of the marker in cancer samples and a representative level for the healthy population. In some cases, the reported dynamic response range covers several orders of magnitude (e.g., \[[@B38-biosensors-08-00132]\]). However, linearity of the analytical response is obtained when the analytical signal is plotted against log marker concentration. In other cases, linearity of the analytical signal against the marker concentration is reported, but in a significantly narrower concentration range. Generally, all calibration graphs represent the Langmuirian curve type, in which the initial sections may approximately follow the strain lines, while the whole curve may be approximately linear when the analytical signal is plotted against log marker concentration (see [Figure 7](#biosensors-08-00132-f007){ref-type="fig"}). Almost all of the reviewed papers containing calibration data report calibration on the basis of a linear calibration graph. This appears to be a reasonable choice, because determination of the logarithm of the marker concentration does not satisfy expectations for clinical results. An example of an application of straight-line calibration is the determination of collagen IV in the plasma of breast cancer patients \[[@B21-biosensors-08-00132]\]. The Langmuirian type calibration contains the initial linear section between 50 and 300 μg L^−1^. However, this relatively narrow concentration range was sufficient for the determination of collagen IV in the plasma samples of breast cancer patients as well as control samples from healthy volunteers. Only two papers refer to semi-log calibration \[[@B7-biosensors-08-00132],[@B15-biosensors-08-00132]\]. The semi-log calibration curve of cytokeratin-19 from 0.01 to 100 pg L^−1^ is reported by Chiu et al. \[[@B7-biosensors-08-00132]\], with a detection limit equal to 1 fg L^−1^. However, the physiological level of the marker is 3 ng L^−1^, three orders of magnitude above the range of applicability of the biosensor. No attempt to determine cytokeratin-19 concentration in real samples was undertaken.

7. Markers {#sec7-biosensors-08-00132}
==========

In the reviewed papers, the targets of the developed or merely applied biosensors are various types of cancer, as well as other diseases. These targets are listed in [Table 5](#biosensors-08-00132-t005){ref-type="table"}. Lung, bladder, and breast cancers are most frequently represented. Single papers have been devoted to colorectal, prostate, and head and neck squamous cell cancers, as well as acute leukemia. Among non-cancer applications, thermal injuries have been most frequently investigated, as well as acute myocardial infarction and acute appendicitis. Papers devoted to apoptosis, asthma, megaloblastic anemia, Parkinson's disease, hypertension, primary renal disease, and diabetes have also been published. Some biosensors have found applications with several diseases; for example, 20S proteasome and UCHL1. In the majority of cases, the biosensors were used for the determination of markers in the blood serum or plasma, although in several cases urine was the target body fluid.

8. Molecular Interactions {#sec8-biosensors-08-00132}
=========================

Apart from the papers devoted to the determination of particular markers in body fluids, several papers on SPR describe investigations of molecular interactions. One of these \[[@B47-biosensors-08-00132]\] describes the interactions of immobilized Cancer Antigen 125 (CA 125) with several aptamers. Elsewhere, the interaction between recombinant Smurf2 protein and CNKSR2 protein was described \[[@B48-biosensors-08-00132]\]. Other studies have investigated the parameters of binding between galectin-3 and pectin \[[@B49-biosensors-08-00132]\] and the glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM) \[[@B50-biosensors-08-00132]\]. A further study \[[@B51-biosensors-08-00132]\] investigated the affinity and competitive inhibition of nine caffeoylquinic acid compounds (CQAs) against programmed cell death protein 1 (PD-1) and its ligand PD-L1. Another investigation concerned the binding affinities of prostate-specific antigen to six lectins \[[@B52-biosensors-08-00132]\], and elsewhere, the ability of nanobody-targeting VEGFR (NTV1) to bind VEGFR2 D3 was demonstrated \[[@B53-biosensors-08-00132]\]. Generally, the aim of these papers is to investigate anti-cancer drugs and therapies. For example, in the last case \[[@B53-biosensors-08-00132]\], the nanobody NTV1 (antibody part containing the antibody domain) is presumed to have antiangiogenic properties due to the blocking of VEGFR2, which is a significant element in the triggering of cancer angiogenesis. SPR measurements were used for the determination of the binding constant of NTV1 to VERFR2. This possibility is available only with classical SPR and the fluidic type of measurement.

9. Conclusions {#sec9-biosensors-08-00132}
==============

The reviewed papers are categorized into five groups, depending on the degree of maturity of the reported solution; ranging from simple marker detection to clinical application of a previously developed biosensor. A majority of the reviewed papers represent validated biosensors and related analytical procedures. Numerous papers report clinical investigations with cancer markers and other diseases as the targets of biosensors.

Some of the reviewed papers used fluidic measurement arrangements, while others used stationary non-fluidic measurement with an array of measuring points. In spite of the significant differences in the measuring process, both versions are successfully used in the determination of various markers. Unfortunately, no information has yet been published concerning the comparison of fluidic and non-fluidic versions of SPR measurements. As regards instrumental solutions, both classical SPR and SPR imaging are almost equally represented. The imaging version is frequently associated with non-fluidic measurement. The fluidic version in combination with classical SPR provides an opportunity to determine the binding constant of molecular interactions.

The selection of a biosensor receptor is mostly determined by the chemical structure of the marker to be analyzed. Antibodies are the most frequently used type of receptors, in combination with the EDC/NHS protocol applied for the covalent attachment of an antibody to the biosensor surface via a suitable linker. Occasionally, marker inhibitors or marker-imprinted polymers have been used as receptors.

Several approaches to marker signal enhancement have been reported. A sandwich structure---consisting of a first antibody, a marker, and an aggregate consisting of a gold nanoparticle covered by a second antibody---has been used, as has preconcentration of a marker with magnetic nanoparticles.

As regards calibration strategy, all calibration graphs represent the Langmuirian curve type, in which the initial sections may approximately follow the strain lines, while the whole curve may be approximately linear when the analytical signal is plotted against log marker concentration. Almost all of the reviewed papers containing calibration data report calibration on the basis of a linear calibration graph, although semi-logarithmic curves were also used.

Several papers have reported molecular interactions. The possibility of determining the binding constant of interacting molecules is available only with classical SPR and the fluidic type of measurement.
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![Example of fluidic SPR measurement. Reproduced with permission from \[[@B4-biosensors-08-00132]\]. Copyright (2018) Elsevier BV.](biosensors-08-00132-g001){#biosensors-08-00132-f001}

![An array of gold nanohole measuring points used in microfluidic measurement. Reproduced with permission from \[[@B3-biosensors-08-00132]\]. Copyright 2015, Springer Science Business Media New York.](biosensors-08-00132-g002){#biosensors-08-00132-f002}

![Example of non-fluidic measurement. Reproduced with permission from \[[@B27-biosensors-08-00132]\]. Copyright 2017 Elsevier B.V.](biosensors-08-00132-g003){#biosensors-08-00132-f003}

![Example of covalent antibody immobilization (**c**) and picture of the chip (**a**) and image of the chip obtained by a CCD camera (**b**). Reproduced from \[[@B22-biosensors-08-00132]\] with permission of Royal Society of Chemistry.](biosensors-08-00132-g004){#biosensors-08-00132-f004}

![Example of receptor immobilization via hydrophobic interaction. Reproduced from \[[@B24-biosensors-08-00132]\] with permission of Royal Society of Chemistry.](biosensors-08-00132-g005){#biosensors-08-00132-f005}

![Example of the use of nanoparticles for SPR signal enhancement. (**a**) Scheme of nanparticles processing, (**b**) sandwich assay. Reproduced with permission from \[[@B38-biosensors-08-00132]\]. Copyright 2017, Springer-Verlag Berlin Heidelberg.](biosensors-08-00132-g006){#biosensors-08-00132-f006}

![Typical calibration curves.](biosensors-08-00132-g007){#biosensors-08-00132-f007}

biosensors-08-00132-t001_Table 1

###### 

Technical solutions for biosensors in the initial stages of development.

  Stage   Marker           SPR Type   Fluidic/Non Fluidic      Chip                     Linker/Receptor                          Receptor Immobilization               Reference
  ------- ---------------- ---------- ------------------------ ------------------------ ---------------------------------------- ------------------------------------- --------------------------------
  i       HER2             SPR        Micro-fluidic            Nano-whole array         Cysteamina/Sandwich/2Antibodies          Biotin/streptavidin                   \[[@B3-biosensors-08-00132]\]
  i       CEA              SPR        Fluidic                  Slide/Cr/Au              MUA/antibody                             EDC/NHS                               \[[@B4-biosensors-08-00132]\]
  i       Cytokeratin 17   SPR        Non fluidic              Optical fiber/Au         S2PEG6COOH/antibody                      EDC/NHS                               \[[@B5-biosensors-08-00132]\]
  i       Cytochrom C      SPRi       Fluidic                  Easy2Spot                Antibody                                 Sensor pre-activated G-type Senseye   \[[@B6-biosensors-08-00132]\]
  i       BSA              SPR        Fluidic or Non fluidic   Prism/Au                 Cysteamine/GOCOOOH/antibody              EDC/NHS                               \[[@B7-biosensors-08-00132]\]
  i       BSA              SPR        Non fluidic              Slide/Au                 Mercapto-propane sulfonate/modified GO   EDC/NHS                               \[[@B8-biosensors-08-00132]\]
  i       BSA Biotin       SPR        Micro-fluidic            Nanogroove metasurface   None streptavidin                        Physisorption/Streptavidin/biotin     \[[@B9-biosensors-08-00132]\]
  ii      Cytokeratin-19   SPR        Fluidic or Non fluidic   Prism                    Cysteamine/GOCOOOH/antibody              EDC/NHS                               \[[@B10-biosensors-08-00132]\]
  ii      Transferrin      SPR        Fluidic                  Slide/Au                 4-Mercapto phenylboronic                 4-Mercapto phenylboronic              \[[@B11-biosensors-08-00132]\]
  ii      Folic acid       SPR        Fluidic                  Prism/Ti/Au/graphen      FAP                                      Hydrophobic interaction               \[[@B12-biosensors-08-00132]\]
  ii      DNA *E. coli*    LSPR       Micro-fluidic            Slide/Ag nano prism      5′\[C6-thiol\] DNA probe                 DNA probe-DNA target interaction      \[[@B13-biosensors-08-00132]\]

EDC/NHS---covalent amide bond formed due to the EDC/NHS protocol. EDS-1(ethyl-3-(dimethylaminopropyl)carboimide NHS-N-Hydroxysulfosuccinoimide, FAP-folic acid protein

biosensors-08-00132-t002_Table 2

###### 

Technical solutions for biosensors representing completely developed procedures.

  Stage   Marker                    SPR Type   Fluidic/Non Fluidic   Chip             Linker/Receptor                         Receptor Immobilization    Reference
  ------- ------------------------- ---------- --------------------- ---------------- --------------------------------------- -------------------------- --------------------------------
  Iii     PSA                       SPRi       Fluidic               Slide/Au         Allyl mercaptan                         PSA imprinted polymer      \[[@B14-biosensors-08-00132]\]
  Iii     CBP                       SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B15-biosensors-08-00132]\]
  Iii     Troponin T                SPR        Fluidic               Slide/Au         Polydopamine/Epitop/                    Polymer Imprinted epitop   \[[@B16-biosensors-08-00132]\]
  Iv      Rac1, Rac1b               SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B17-biosensors-08-00132]\]
  Iv      5LOX                      SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B18-biosensors-08-00132]\]
  Iv      CDK4                      SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B19-biosensors-08-00132]\]
  Iv      Laminin-5                 SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                     EDC/NHS                    \[[@B20-biosensors-08-00132]\]
  Iv      Collagen IV               SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                     EDC/NHS                    \[[@B21-biosensors-08-00132]\]
  Iv      MMP1                      SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                     EDC/NHS                    \[[@B22-biosensors-08-00132]\]
  Iv      20S immune-proteasome     SPRi       Non fluidic           Slide/Au/array   1-octadecano-thiol/Inhibitor ONX 0914   Hydrophobic interaction    \[[@B23-biosensors-08-00132]\]
  Iv      MMP2                      SPRi       Non fluidic           Slide/Au/array   1-octadecano-thiol/Inhibitor ARP 101    Hydrophobic interaction    \[[@B24-biosensors-08-00132]\]
  Iv      YKL40                     SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B25-biosensors-08-00132]\]
  Iv      Mortalin and αSynuclein   SPR        Fluidic               CM5 chip         Dextran-COOH/Antibody                   EDC/NHS                    \[[@B26-biosensors-08-00132]\]
  Iv      Fibronectin               SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                     EDC/NHS                    \[[@B27-biosensors-08-00132]\]

EDC/NHS---covalent amide bond formed due to the EDC/NHS protocol.

biosensors-08-00132-t003_Table 3

###### 

Technical solutions for developed biosensors applied in clinical investigations.

  Stage   Marker                      SPR Type   Fluidic/Non Fluidic   Chip             Linker/Receptor                                             Receptor Immobilization           Reference
  ------- --------------------------- ---------- --------------------- ---------------- ----------------------------------------------------------- --------------------------------- -----------------------------------------------------------
  V       podoplanin                  SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                                         EDC/NHS                           \[[@B28-biosensors-08-00132]\]
  V       20S proteasome              SPRi       Non fluidic           Slide/Au/array   Cysteamine/Inhibitor PSI                                    EDC/NHS                           \[[@B29-biosensors-08-00132]\]
  V       Cystatin C                  SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                                         EDC/NHS                           \[[@B30-biosensors-08-00132]\]
  V       UCHL1                       SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                                         EDC/NHS                           \[[@B31-biosensors-08-00132]\]
  V       MMP2 Laminin5 Collagen IV   SPRi       Non fluidic           Slide/Au/array   1-octadecano-thiol/Inhibitor ONX 0914 Cysteamine/antibody   Hydrophobic Interaction EDC/NHS   \[[@B32-biosensors-08-00132]\]
  V       UCHL1                       SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                                         EDC/NHS                           \[[@B33-biosensors-08-00132]\]
  V       20S proteasome              SPRi       Non fluidic           Slide/Au/array   Cysteamine/Inhibitor PSI                                    EDC/NHS                           \[[@B34-biosensors-08-00132]\]
  V       UCHL1                       SPRi       Non fluidic           Slide/Au/array   Cysteamine/Antibody                                         EDC/NHS                           \[[@B35-biosensors-08-00132],[@B36-biosensors-08-00132]\]
  V       20S proteasome              SPRi       Non fluidic           Slide/Au/array   Cysteamine/Inhibitor PSI                                    EDC/NHS                           \[[@B37-biosensors-08-00132]\]

EDC/NHS---covalent amide bond formed due to the EDC/NHS protocol.

biosensors-08-00132-t004_Table 4

###### 

Stages of biosensor development and technical solutions for biosensors with the use of nanoparticles.

  Stage   Marker                SPR Type   Fluidic/Non Fluidic   Chip/NP                     Sandwich/Other         Receptors Immobilization (Chip/Antibody)         Reference
  ------- --------------------- ---------- --------------------- --------------------------- ---------------------- ------------------------------------------------ --------------------------------
  ii      Folic acid            SPRi       Non fluidic           Array/Cr/Au/FA-AuNP         Sandwich               HS-(CH2)11-EG3-NTA/polyhistidine                 \[[@B12-biosensors-08-00132]\]
  ii      Troponin I            SPR        Fluidic               Slide/Au/HGNP/MMWCNTs-PDA   Sandwich/MMWCNTs-PDA   Polydopamine/Polydopamine                        \[[@B45-biosensors-08-00132]\]
  iii     CEA                   SPR        Fluidic               Slide/Ti/Au/AuNP            Sandwich               HS-OEG-COOH/HS-OEG-COOH/EDC/NHS                  \[[@B38-biosensors-08-00132]\]
  iii     HER 2                 SPR        Micro-fluidic         Prism/Au/SAv-GNPs           Sandwich               MUA/EDC/NHS/biotinylated antibody                \[[@B43-biosensors-08-00132]\]
  iv      Cytochrom C           SPR        Fluidic               Slide/Au/AuNR               Sandwich/MMP           Straptavidin/biotinylated aptamer/antibody/MMP   \[[@B44-biosensors-08-00132]\]
  iv      AFP, CEA CYFRA 21-1   SPR        Micro-fluidic         Prism/Au                    Sandwich/QD            Hexanedithiol/antibody/DTBE                      \[[@B46-biosensors-08-00132]\]

SAv-GNPs---streptavidin decorated gold nanoparticles. FA-AuNP---AuNP functionalized with polyhistidine tagged folic acid binding protein. AuNR---Au nanorods. MMP---micro magnetic particles. QD---quantum dot (CdSe/ZnS core/shell structure). DTBE---2,2′-dithiobis \[1-(2-bromo-2-methylpropionyloxy)\]ethane. AFP---α-fetoprotein. MMWCNTs-PDA---polydopamine-wrapped magnetic multi-walled carbon nanotubes. HGNP---hollow gold nanoparticles.

biosensors-08-00132-t005_Table 5

###### 

Markers and related diseases.

  Marker                                             Abbrev.         Cancer/or Other Disease                          Body Fluid           Reference
  -------------------------------------------------- --------------- ------------------------------------------------ -------------------- --------------------------------------------------------------------------------------
  Arachidonate 5-lipoxygenase                        5LOX/ALOX5      Breast cancer                                    Blood plasma         \[[@B18-biosensors-08-00132]\]
  Carcinoembryonic antigen                           CEA             Colorectal cancer                                Blood serum          \[[@B4-biosensors-08-00132]\]
  Calcium Binding Protein                            CBP             Acute myocardial infarction                      Blood serum          \[[@B15-biosensors-08-00132]\]
  Chitinase-3-like protein 1                         CHI3L1/YKL-40   Asthma                                           Blood serum          \[[@B25-biosensors-08-00132]\]
  Collagen IV                                                        Breast cancer/burns                              Blood serum          \[[@B21-biosensors-08-00132]\]
  Cyclin-dependent kinase 4                          CDK4            Lung, head and neck cancers                      Blood serum          \[[@B19-biosensors-08-00132]\]
  Cystatin C                                                         Bladder cancer                                   Blood serum, urine   \[[@B30-biosensors-08-00132]\]
  Cytochrom C                                                        Apoptosis                                        No information       \[[@B6-biosensors-08-00132]\]
  Cytokeratin 17                                     CK 17           Lung cancer                                      No information       \[[@B5-biosensors-08-00132]\]
  Cytokeratin 19                                     CK19            Lung cancer                                      Blood plasma         \[[@B10-biosensors-08-00132]\]
  Epidermal receptor protein-2 antigen               HER             Breast cancer                                    No information       \[[@B3-biosensors-08-00132]\]
  Fibronectin                                                        Burns                                            Blood plasma         \[[@B27-biosensors-08-00132]\]
  Folic acid                                         FA              Megaloblastic anemia                             blood                \[[@B12-biosensors-08-00132]\]
  20S-immunoproteasom                                20Si            Acute leukemia                                   Blood plasma         \[[@B23-biosensors-08-00132]\]
  Laminin 5                                                          Bladder cancer/burns                             Blood plasma         \[[@B20-biosensors-08-00132],[@B32-biosensors-08-00132]\]
  Matrix metalloproteinase-1                         MMP1            Bladder cancer/acute appendicitis                Blood serum          \[[@B22-biosensors-08-00132]\]
  Matrix metalloproteinase-2                         MMP2            Burns                                            Blood plasma         \[[@B24-biosensors-08-00132],[@B32-biosensors-08-00132]\]
  Mortalin/mitochondrial 70 kDa heat shock protein   mtHsp70         Parkinson's Disease                              Blood serum          \[[@B26-biosensors-08-00132]\]
  Podoplanin                                                         Bladder cancer                                   Blood serum, urine   \[[@B28-biosensors-08-00132]\]
  20S-proteasom                                      20Sc            Burns, acute appendicitis, Cryptorchidism        Blood plasma         \[[@B34-biosensors-08-00132]\]
  Prostate specific antigen                          PSA             Prostate cancer                                  Blood serum          \[[@B14-biosensors-08-00132]\]
  Ras-related C3 botulinum toxin substrate 1         Rac1            Non-Small Cell Lung Cancer                       Blood serum          \[[@B17-biosensors-08-00132]\]
  Ras-related C3 botulinum toxin substrate 1b        Rac1b           Non-Small Cell Lung Cancer                       Blood serum          \[[@B17-biosensors-08-00132]\]
  Transferrin                                        Trf             Hypertension, primary renal disease, diabetes.   Artificial urine     \[[@B11-biosensors-08-00132]\]
  Troponin T                                         TnT             Acute myocardial infarction                      Blood serum          \[[@B16-biosensors-08-00132]\]
  Ubiquitin carboxyl-terminal hydrolase L1           UCHL1           Burns, cryptorchidism, Acute Appendicitis        Blood serum          \[[@B31-biosensors-08-00132],[@B35-biosensors-08-00132],[@B36-biosensors-08-00132]\]
